{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:54:29Z","timestamp":1781801669262,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,20]]},"DOI":"10.7759\/cureus.54565","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T21:00:47Z","timestamp":1708462847000},"source":"Crossref","is-referenced-by-count":16,"title":["Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice"],"prefix":"10.7759","author":[{"given":"Ahmed  I","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J","family":"Plaisance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles  P","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsi J","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1039\/c9md00120d","article-title":"Quinolone antibiotics","volume":"10","author":"Pham TD","year":"2019","unstructured":"Pham TD, Ziora ZM, Blaskovich MA. Quinolone antibiotics. Medchemcomm. 2019, 10:1719-39. 10.1039\/c9md00120d","journal-title":"Medchemcomm"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph0303s57","article-title":"Topoisomerase assays","volume":"Chapter 3","author":"Nitiss JL","year":"2012","unstructured":"Nitiss JL, Soans E, Rogojina A, Seth A, Mishina M. Topoisomerase assays. Curr Protoc Pharmacol. 2012, Chapter 3:Unit 3.3.. 10.1002\/0471141755.ph0303s57","journal-title":"Curr Protoc Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.09.020","article-title":"Neurotoxicity with antimicrobials in the elderly: a review","volume":"36","author":"Mattappalil A","year":"2014","unstructured":"Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014, 36:1489-1511.e4. 10.1016\/j.clinthera.2014.09.020","journal-title":"Clin Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya S","year":"2016","unstructured":"Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology. 2016, 86:963-71. 10.1212\/WNL.0000000000002455","journal-title":"Neurology"},{"key":"ref5","article-title":"Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury","year":"2018","unstructured":"Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2018."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2017.11.001","article-title":"Fluoroquinolone-related neuropsychiatric events in hospitalized veterans","volume":"59","author":"Sellick J","year":"2018","unstructured":"Sellick J, Mergenhagen K, Morris L, et al.. Fluoroquinolone-related neuropsychiatric events in hospitalized veterans\r\n. Psychosomatics. 2018, 59:259-66. 10.1016\/j.psym.2017.11.001","journal-title":"Psychosomatics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones SC","year":"2011","unstructured":"Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011, 34:839-47. 10.2165\/11593110-000000000-00000","journal-title":"Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales D","year":"2019","unstructured":"Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurol. 2019, 76:827-33. 10.1001\/jamaneurol.2019.0887","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K347","article-title":"Safety concerns with fluoroquinolones","volume":"41","author":"Mehlhorn AJ","year":"2007","unstructured":"Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007, 41:1859-66. 10.1345\/aph.1K347","journal-title":"Ann Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: a systematic review","volume":"85","author":"Sutter R","year":"2015","unstructured":"Sutter R, R\u00fcegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015, 85:1332-41. 10.1212\/WNL.0000000000002023","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001805","article-title":"Seizures and quinolone antibiotics in children: a systematic review of adverse events","volume":"27","author":"Neame M","year":"2020","unstructured":"Neame M, King C, Riordan A, Iyer A, Kneen R, Sinha I, Hawcutt DB. Seizures and quinolone antibiotics in children: a systematic review of adverse events. Eur J Hosp Pharm. 2020, 27:60-4. 10.1136\/ejhpharm-2018-001805","journal-title":"Eur J Hosp Pharm"},{"key":"ref12","unstructured":"Fluoroquinolones antibiotics. Cipro, Levaquin & Avelox. (2023). Accessed: December 30, 2023: https:\/\/www.drugwatch.com\/cipro-levaquin-avelox\/."},{"key":"ref13","unstructured":"Floxed by Cipro at 22. \"A bomb went off in my body\". (2020). Accessed: December 30, 2023: https:\/\/www.drugwatch.com\/beyond-side-effects\/floxed-by-cipro-at-22-a-bomb-went-off-in-my-body\/.."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8023935","article-title":"Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications","volume":"2017","author":"Michalak K","year":"2017","unstructured":"Michalak K, Sobolewska-W\u0142odarczyk A, W\u0142odarczyk M, Sobolewska J, Wo\u017aniak P, Sobolewski B. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications\r\n. Oxid Med Cell Longev. 2017, 2017:8023935. 10.1155\/2017\/8023935","journal-title":"Oxid Med Cell Longev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: management considerations","volume":"72","author":"Grill MF","year":"2011","unstructured":"Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011, 72:381-93. 10.1111\/j.1365-2125.2011.03991.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13039","article-title":"Levofloxacin and seizures: what risk for elderly adults?","volume":"62","author":"Famularo G","year":"2014","unstructured":"Famularo G, Pizzicannella M, Gasbarrone L. Levofloxacin and seizures: what risk for elderly adults?. J Am Geriatr Soc. 2014, 62:2018-9. 10.1111\/jgs.13039","journal-title":"J Am Geriatr Soc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0377-1237(06)80116-4","article-title":"Association of a Tourette-like syndrome with sparfloxacin","volume":"62","author":"Brar KS","year":"2006","unstructured":"Brar KS, Kumar V, Johri S. Association of a Tourette-like syndrome with sparfloxacin. Med J Armed Forces India. 2006, 62:381-2. 10.1016\/S0377-1237(06)80116-4","journal-title":"Med J Armed Forces India"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617752736","article-title":"Quinolone-induced painful peripheral neuropathy: a case report and literature review","volume":"6","author":"Estofan LJ","year":"2018","unstructured":"Estofan LJ, Naydin S, Gliebus G. Quinolone-induced painful peripheral neuropathy: a case report and literature review. J Investig Med High Impact Case Rep. 2018, 6:2324709617752736. 10.1177\/2324709617752736","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1831","article-title":"Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model","volume":"42","author":"Schmuck G","year":"1998","unstructured":"Schmuck G, Sch\u00fcrmann A, Schl\u00fcter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 1998, 42:1831-6. 10.1128\/AAC.42.7.1831","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199207040-00003","article-title":"Drug interactions with quinolone antibacterials","volume":"7","author":"Brouwers JR","year":"1992","unstructured":"Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf. 1992, 7:268-81. 10.2165\/00002018-199207040-00003","journal-title":"Drug Saf"},{"key":"ref21","unstructured":"FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. (2023). Accessed. December 30, 2023 : https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-v...."},{"key":"ref22","unstructured":"FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears. (2023). Accessed. December 30, 2023 : https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2019\/11\/fda-warning-about-fluoroquinolones...."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2174\/1871525717666190402121958","article-title":"Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: a systematic review and meta-analysis","volume":"17","author":"Rawla P","year":"2019","unstructured":"Rawla P, El Helou ML, Vellipuram AR. Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: a systematic review and meta-analysis\r\n. Cardiovasc Hematol Agents Med Chem. 2019, 17:3-10. 10.2174\/1871525717666190402121958","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis A","year":"2011","unstructured":"Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011, 120:103-10. 10.1159\/000334441","journal-title":"Cardiology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jat.2903","article-title":"Cytotoxic effects of the quinolone levofloxacin on rabbit meniscus cells","volume":"34","author":"Wang L","year":"2014","unstructured":"Wang L, Wu Y, Tan Y, et al.. Cytotoxic effects of the quinolone levofloxacin on rabbit meniscus cells. J Appl Toxicol. 2014, 34:870-7. 10.1002\/jat.2903","journal-title":"J Appl Toxicol"},{"key":"ref26","article-title":"The metabolic effects of quinolones and steroids on human ligament cells: an in vitro study","volume":"34","author":"Luciani P","year":"2020","unstructured":"Luciani P, Bottegoni C, Manzotti S, Solfanelli G, Farinelli L, Gigante A. The metabolic effects of quinolones and steroids on human ligament cells: an in vitro study. J Biol Regul Homeost Agents. 2020, 34:93-99. IORS Special Issue on Orthopedics.","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones. an overview on mechanistic aspects","volume":"8","author":"De Sarro A","year":"2001","unstructured":"De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. Curr Med Chem. 2001, 8:371-84. 10.2174\/0929867013373435","journal-title":"Curr Med Chem"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2011.08.019","article-title":"The effects of levofloxacin on rabbit anterior cruciate ligament cells in vitro","volume":"257","author":"Deng Y","year":"2011","unstructured":"Deng Y, Chen B, Qi Y, Magdalou J, Wang H, Chen L. The effects of levofloxacin on rabbit anterior cruciate ligament cells in vitro. Toxicol Appl Pharmacol. 2011, 257:67-73. 10.1016\/j.taap.2011.08.019","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-007-9024-8","article-title":"The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro","volume":"32","author":"Lim S","year":"2008","unstructured":"Lim S, Hossain MA, Park J, Choi SH, Kim G. The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro. Vet Res Commun. 2008, 32:243-53. 10.1007\/s11259-007-9024-8","journal-title":"Vet Res Commun"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2007.08.025","article-title":"Ofloxacin induces apoptosis in microencapsulated juvenile rabbit chondrocytes by caspase-8-dependent mitochondrial pathway","volume":"226","author":"Sheng Z","year":"2008","unstructured":"Sheng Z, Cao X, Peng S, Wang C, Li Q, Wang Y, Liu M. Ofloxacin induces apoptosis in microencapsulated juvenile rabbit chondrocytes by caspase-8-dependent mitochondrial pathway. Toxicol Appl Pharmacol. 2008, 226:119-27. 10.1016\/j.taap.2007.08.025","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.20049","article-title":"Tendon and ligament: development, repair and disease","volume":"75","author":"Tozer S","year":"2005","unstructured":"Tozer S, Duprez D. Tendon and ligament: development, repair and disease. Birth Defects Res C Embryo Today. 2005, 75:226-36. 10.1002\/bdrc.20049","journal-title":"Birth Defects Res C Embryo Today"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.009","article-title":"Synergistic effects of dexamethasone and quinolones on human-derived tendon cells","volume":"35","author":"Sendzik J","year":"2010","unstructured":"Sendzik J, Shakibaei M, Sch\u00e4fer-Korting M, Lode H, Stahlmann R. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents. 2010, 35:366-74. 10.1016\/j.ijantimicag.2009.10.009","journal-title":"Int J Antimicrob Agents"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020143","article-title":"A VigiBase descriptive study of fluoroquinolone-associated peripheral nervous system disorders","volume":"15","author":"Huruba M","year":"2022","unstructured":"Huruba M, Farcas A, Leucuta DC, Bucsa C, Mogosan C. A VigiBase descriptive study of fluoroquinolone-associated peripheral nervous system disorders. Pharmaceuticals (Basel). 2022, 15:143. 10.3390\/ph15020143","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.07.022","article-title":"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect","volume":"123","author":"Kelesidis T","year":"2010","unstructured":"Kelesidis T, Canseco E. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.  Am J Med. 2010, 123:e5-6. 10.1016\/j.amjmed.2009.07.022","journal-title":"Am J Med"},{"key":"ref35","unstructured":"FDA Updates Warnings for Fluoroquinolone Antibiotics. (2023). Accessed. December 30, 2023: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1086\/428052","article-title":"Mechanisms of resistance to quinolones","volume":"41 Suppl 2","author":"Jacoby GA","year":"2005","unstructured":"Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005, 41 Suppl 2:S120-6. 10.1086\/428052","journal-title":"Clin Infect Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.16.5.455","article-title":"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients","volume":"16","author":"Biggs WS","year":"2003","unstructured":"Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract. 2003, 16:455-7. 10.3122\/jabfm.16.5.455","journal-title":"J Am Board Fam Pract"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.111908","article-title":"Recurrent episodes of hypoglycemia induced by moxifloxacin","volume":"45","author":"Singal DK","year":"2013","unstructured":"Singal DK, Mittal A, Prakash A. Recurrent episodes of hypoglycemia induced by moxifloxacin. Indian J Pharmacol. 2013, 45:301-2. 10.4103\/0253-7613.111908","journal-title":"Indian J Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00428","article-title":"Quinolones-induced musculoskeletal, neurological, and psychiatric ADRs: a pharmacovigilance study based on data From the Italian spontaneous reporting system","volume":"11","author":"Scavone C","year":"2020","unstructured":"Scavone C, Mascolo A, Ruggiero R, Sportiello L, Rafaniello C, Berrino L, Capuano A. Quinolones-induced musculoskeletal, neurological, and psychiatric ADRs: a pharmacovigilance study based on data From the Italian spontaneous reporting system. Front Pharmacol. 2020, 11:428. 10.3389\/fphar.2020.00428","journal-title":"Front Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8030104","article-title":"Adverse effects of fluoroquinolones: a retrospective cohort study in a south Indian tertiary healthcare facility","volume":"8","author":"Mathews B","year":"2019","unstructured":"Mathews B, Thalody AA, Miraj SS, Kunhikatta V, Rao M, Saravu K. Adverse effects of fluoroquinolones: a retrospective cohort study in a south Indian tertiary healthcare facility. Antibiotics (Basel). 2019, 8:10.3390\/antibiotics8030104","journal-title":"Antibiotics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/227939-fluoroquinolones-neurological-complications-and-side-effects-in-clinical-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T21:00:52Z","timestamp":1708462852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/227939-fluoroquinolones-neurological-complications-and-side-effects-in-clinical-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.54565","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}